Ratio Examination: Heron Therapeutics Inc (HRTX)’s Price-to-Cash and Price-to-Free Cash Flow

Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

In the latest session, Heron Therapeutics Inc (NASDAQ: HRTX) closed at $2.74 down -21.04% from its previous closing price of $3.47. In other words, the price has decreased by -$21.04 from its previous closing price. On the day, 7.5 million shares were traded. HRTX stock price reached its highest trading level at $3.47 during the session, while it also had its lowest trading level at $2.71.


For a deeper understanding of Heron Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.90 and its Current Ratio is at 2.47.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Rodman & Renshaw on June 13, 2024, initiated with a Buy rating and assigned the stock a target price of $7.

On April 23, 2024, CapitalOne started tracking the stock assigning a Overweight rating and target price of $6.

Needham reiterated its Buy rating for the stock on March 13, 2024, while the target price for the stock was revised from $4 to $5.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 17 ’23 when Forbes William P bought 25,000 shares for $1.09 per share. The transaction valued at 27,250 led to the insider holds 79,000 shares of the business.

Collard Craig A bought 150,000 shares of HRTX for $137,970 on Nov 16 ’23. The Chief Executive Officer now owns 186,496 shares after completing the transaction at $0.92 per share. On Nov 16 ’23, another insider, Duarte Ira, who serves as the EVP, Chief Financial Officer of the company, bought 85,000 shares for $0.89 each. As a result, the insider paid 75,599 and bolstered with 85,000 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HRTX now has a Market Capitalization of 522767360 and an Enterprise Value of 520436640. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.12. Its current Enterprise Value per Revenue stands at 3.94 whereas that against EBITDA is -8.41.

Stock Price History:

The Beta on a monthly basis for HRTX is 1.81, which has changed by 1.302521 over the last 52 weeks, in comparison to a change of 0.23886502 over the same period for the S&P500. Over the past 52 weeks, HRTX has reached a high of $3.93, while it has fallen to a 52-week low of $0.50. The 50-Day Moving Average of the stock is -13.49%, while the 200-Day Moving Average is calculated to be 26.66%.

Shares Statistics:

For the past three months, HRTX has traded an average of 2.23M shares per day and 3132950 over the past ten days. A total of 150.29M shares are outstanding, with a floating share count of 139.45M. Insiders hold about 7.44% of the company’s shares, while institutions hold 72.67% stake in the company. Shares short for HRTX as of 1718323200 were 30465169 with a Short Ratio of 13.65, compared to 1715731200 on 30268749. Therefore, it implies a Short% of Shares Outstanding of 30465169 and a Short% of Float of 26.200000000000003.

Most Popular